Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca, with a price target of p18,900.00.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

According to TipRanks, Smith is a 4-star analyst with an average return of 11.0% and a 68.10% success rate. Smith covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Roche Holding AG.

In addition to Bernstein, AstraZeneca also received a Buy from Bank of America Securities’s Sachin Jain in a report issued today. However, on June 30, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).

Based on AstraZeneca’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p15.29 billion and a net profit of p3.08 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p3 billion

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.